Healthy Clinical Trial
Official title:
Bioequivalence Study of Fasting Oral Perindopril Tert-butylamine Tablets in Healthy Subjects With a Single-dose, Randomized, Open, Two-cycle, Crossover Trial Design
Verified date | September 2020 |
Source | Sichuan Haisco Pharmaceutical Group Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In order to evaluate the bioequivalence of the test preparations and reference preparations of perindopril tert-butylamine tablets after meal and their safety in Chinese adult healthy subjects.
Status | Completed |
Enrollment | 32 |
Est. completion date | March 15, 2019 |
Est. primary completion date | March 8, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: 1. Healthy volunteers between the ages of 18 and 50 (including cut-off values), both male and female; 2. Male weight =50kg, female weight =45kg, and body mass index (BMI) 19-26kg/m2 (including cut-off values); 3. Sign the informed consent form voluntarily; 4. Be able to maintain good communication with researchers and comply with various requirements of clinical trials. Exclusion Criteria: 1. People who is addicted to alcohol, tobacco,(drink 14 units of alcohol per week within the first month of enrollment: 1 unit = 285 ml of beer, or 25 ml of spirits, or 1 glass of wine; average daily smoking in the 3 months before screening =5) and/or those who cannot ban smoking and alcohol during the trial; or those who have a positive result alcohol breath trial; 2. Use any prescription drugs (such as antihypertensive drugs) within 4 weeks before screening, or use any over-the-counter drugs (vitamins, Chinese herbal tonics) within 2 weeks before screening, or take foods that affect metabolism within 2 weeks before screening, such as grapefruit or a drink containing grapefruit (acetaminophen can be used, but it must be recorded in the concomitant medication of CRF); or the subject refused to stop using foods that affect CYP1A2 during the trial, such as coffee, tea, cola, chocolate, etc. 3. Those who have used any drugs with a long half-life that may affect this study, or have participated in any drug clinical trials as subjects in the past 3 months; 4. Blood donation or blood loss = 400mL within 8 weeks before the first administration; 5. People with a history of food or drug allergy, or allergies; 6. Any clinically significant physical examination, vital signs, electrocardiogram or clinical laboratory measurement abnormalities during screening; 7. Suffer from blood system, circulatory system, digestive system, urinary system, respiratory system, nervous system, immune system, endocrine system, mental abnormality, metabolic abnormality or any other chronic or serious disease history or existing disease that may affect the results of the study Those with the aforementioned systemic diseases; 8. Human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or Treponema pallidum antibody (TPPA) has a positive result; 9. Those who have a history of drug abuse or drug dependence; 10. People who have a history of fainting needles and blood, or who cannot tolerate venipuncture blood sampling and known serious bleeding tendency; 11. Patients with resting systolic blood pressure =90 mmHg, =140mmHg, or diastolic blood pressure =60 mmHg, =90mmHg, or pulse (HR) =50bpm, =100bpm; 12. Pregnant or lactating women, or female subjects whose pregnancy test results are positive; subjects (or their partners) have birth plans or sperm and egg donors during the entire trial period and within 3 months after the end of the study; trial Those who are unwilling to take one or more physical contraceptive measures during the period and within 3 months after the end of the study; 13. Patients with congenital galactosemia, glucose and galactose malabsorption syndrome, or lack of lactase; 14. Subjects who have poor compliance or who the researcher thinks are not suitable for inclusion in the group. |
Country | Name | City | State |
---|---|---|---|
China | General Hospital of the northern theater of the Chinese people's Liberation Army | Shenyang | Liaoning |
Lead Sponsor | Collaborator |
---|---|
Sichuan Haisco Pharmaceutical Group Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Adverse event rate | Adverse events are summarized according to the system organ classification and standard name, and the system organ classification and standard name are arranged in descending order of the frequency of the tested preparation group | from the screening to 18 days post-dose | |
Primary | Maximum drug concentration (Cmax) of Perindopril | Before administration (within 2 hours) and 10 minutes to 72 hours after administration | ||
Primary | Area under the plasma concentration versus time curve (AUC0-8?AUC0-t)of Perindopril | Before administration (within 2 hours) and 10 minutes to 72 hours after administration | ||
Secondary | Time to reach maximum plasma concentration(Tmax) of Perindopril and Perindoprilat | Before administration (within 2 hours) and 10 minutes to 72 hours after administration | ||
Secondary | Terminal elimination half-life(t1/2 )of Perindopril and Perindoprilat | Before administration (within 2 hours) and 10 minutes to 72 hours after administration | ||
Secondary | Maximum drug concentration (Cmax) of Perindoprilat | fore administration (within 2 hours) and 10 minutes to 72 hours after administration | ||
Secondary | Area under the plasma concentration versus time curve (AUC0-8?AUC0-t)of Perindoprilat | Before administration (within 2 hours) and 10 minutes to 72 hours after administration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |